Mechlorethamine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Mechlorethamine
- Pharmacist Assessment Report
- Mechlorethamine: Relapsing-remitting multiple sclerosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Mechlorethamine: Relapsing-remitting multiple sclerosis
One-Sentence Summary
Mechlorethamine is a nitrogen mustard alkylating agent with cytotoxic and immunosuppressive properties. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis. However, no clinical trials and no publications directly support this prediction, so it remains a model-only hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Relapsing-remitting multiple sclerosis |
| TxGNN Prediction Score | 0.9913 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Mechlorethamine is a bifunctional alkylating agent. Drugs of this class damage DNA and suppress rapidly dividing immune cells, which causes lymphodepletion.
Relapsing-remitting multiple sclerosis (RRMS) is an immune-mediated disease. Some alkylating or cytotoxic agents, such as cyclophosphamide and mitoxantrone, have been used to dampen the immune response in MS. This class-level link is the most plausible reason for the model’s prediction.
The link is indirect, and the safety profile is a major obstacle. Mechlorethamine’s systemic toxicity includes myelosuppression, secondary malignancy, gonadal toxicity and severe tissue vesicant effects. A favourable benefit-risk balance in RRMS is unlikely while safer approved options exist.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 14658L | Ledaga | Topical gel, 160 micrograms (as hydrochloride) per g, 60 g | Indication text not available in the data compiled |
The only marketed Australian form is a topical gel. It is a single-ingredient product with a valid licence. A topical product is not suited to the systemic exposure that an RRMS indication would probably require.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (nitrogen mustard alkylating agent) |
| Myelosuppression Risk | High with systemic exposure (the topical gel carries lower systemic exposure) |
| Emetogenicity Classification | High with systemic intravenous use; not a typical concern with topical use |
| Monitoring Items | FBC with differential, liver and renal function; skin reactions with topical use |
| Handling Protection | Must follow cytotoxic drug handling regulations; avoid skin and eye contact (vesicant) |
Please refer to the Product Information (PI) warnings and precautions for product-specific detail.
Safety Considerations
- Drug Interactions: 100 interactions were recorded. Examples classified as Major:
- Deferiprone
- Samarium (153Sm) lexidronam
- Adalimumab
- Baricitinib
Many Moderate interactions involve other immunosuppressants and myelosuppressive agents (for example azathioprine, mercaptopurine, alemtuzumab) and vaccines. Combining immunosuppressive therapies in MS would need careful review.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (evidence level L5). No trials or publications directly study mechlorethamine in relapsing-remitting multiple sclerosis. The drug’s systemic toxicity and the topical-only Australian formulation argue against pursuing this use now.
To proceed, the following is needed:
- Direct preclinical or clinical evidence in MS, for example animal models of neuroinflammation
- Mechanism of action data to support the proposed immunological link
- A benefit-risk comparison against approved MS disease-modifying therapies
- Route and formulation feasibility, since only a topical gel is marketed in Australia
- Review of the TGA Product Information for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.